Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CRS 207

Next Previous
X
Search
Drug Profile

CRS 207

Alternative Names: ANZ-207; Cancer vaccine - Chinook Therapeutics; CRS-207; Listeria monocytogenes-expressing mesothelin - Chinook Therapeutics

Latest Information Update: 07 Dec 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cerus Corporation; Chugai Pharmaceutical; Johns Hopkins University
  • Developer Aduro BioTech; Merck AG
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants; Megakaryocyte potentiating factor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer; Mesothelioma
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Fallopian tube cancer; Gastric cancer; Malignant-mesothelioma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer

Most Recent Events

  • 23 Aug 2023 Sidney Kimmel Comprehensive Cancer Center completes a phase II trial for Pancreatic cancer (Combination therapy, Second-line therapy or greater, Metastatic disease) in USA (NCT03190265)
  • 11 Aug 2023 Chinook Therapeutics has been acquired by Novartis
  • 05 Oct 2020 Aduro Biotech has been merged with Chinook Therapeutics to form Chinook Therapeutics

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top